Submission of quarterly results for the quarter ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.2 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Novelix Pharmaceuticals (formerly Trimurthi Limited) reported unaudited Q2 FY26 revenue of Rs. 3,538.89 lakhs, up sharply from Rs. 395.66 lakhs in the year-ago quarter. For H1 FY26, revenue stood at Rs. 5,871.01 lakhs versus Rs. 455.66 lakhs in H1 FY25. Net profit for Q2 was Rs. 53.31 lakhs compared to Rs. 12.95 lakhs earlier, while H1 swung to a profit of Rs. 64.03 lakhs from a loss of Rs. 22.44 lakhs a year ago. The company operates in a single segment — manufacturing and trading of pharmaceutical ingredients (bulk drugs). Auditor CVS Balachandra Rao & Co. issued an unmodified limited review report with no qualifications.
Strong year-on-year revenue growth and a return to profitability are positive signals for shareholders, though the company continues to show negative operating cash flows (-Rs. 635.63 lakhs in H1 FY26), indicating earnings quality and cash conversion need monitoring.